TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18377143

Group type: EXPERIMENTAL
Intervention: Hypnotic taper intervention with self-help treatment for insomnia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypnotic taper intervention without self-help treatment for insomnia
Number of subjects: 0
Study: 17178982

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied once daily for 2 weeks (all cohorts)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks (all cohorts)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied once daily for 2 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks
Number of subjects: 31
Study: 15006251

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10783018

Group type: EXPERIMENTAL
Intervention: Positive nasopharyngeal culture for S. pneumoniae in NT‐AOM
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Positive nasopharyngeal culture for S. pneumoniae in NR‐AOM
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for S. pneumoniae in NR‐AOM
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for S. pneumoniae in NT‐AOM
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NT‐AOM
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NR‐AOM
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal colonization with penicillin-nonsusceptible S. pneumoniae in NR‐AOM
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal colonization with penicillin-nonsusceptible S. pneumoniae in NT‐AOM
Number of subjects: 579
Study: 8653625

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium eye drops 0.1% (Naclof)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone eye drops 0.1% (Dexamethasone oph.)
Number of subjects: 60
Study: 1458764

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (20mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral omeprazole (40mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous and oral omeprazole
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison with young individuals
Number of subjects: 14
Study: 6327543

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 600 mg intramuscularly daily for 12 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rifampin 600 mg daily for 21 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of sodium stibogluconate and rifampin
Number of subjects: 32
Study: 30772898

Group type: EXPERIMENTAL
Intervention: Behavioral indications of assent, level of intimacy between the couple, and age of respondent
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Cognition and relationship levels
Number of subjects: 389
Study: 29804728

Group type: EXPERIMENTAL
Intervention: Responders to frontline therapy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Disease stabilization
Number of subjects: 305
Study: 27902612

Group type: EXPERIMENTAL
Intervention: Nonstyletted endotracheal tube with exaggerated curvature
Number of subjects: 140

Group type: COMPARATOR
Intervention: Styletted endotracheal tube
Number of subjects: 140
Study: 24812022

Group type: COMPARATOR
Intervention: Basic Internet (BI)
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Enhanced Internet (EI)
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Enhanced Internet plus telephone counseling (EI+P)
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Non-assigned treatments (pharmacotherapy, behavioral, alternative, non-study Internet)
Number of subjects: 2005
Study: 22445846

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20482243

Group type: EXPERIMENTAL
Intervention: Insulin lispro pen
Number of subjects: 367
Study: 19018255

Group type: EXPERIMENTAL
Intervention: Individual support
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Group rehabilitation
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Combination of individual support and group rehabilitation
Number of subjects: 481

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 481
Study: 15282351

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin
Number of subjects: 868

Group type: COMPARATOR
Intervention: interferon alfa‐2a plus ribavirin
Number of subjects: 868

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin (HCV genotype 1)
Number of subjects: 868

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo (HCV genotype 1)
Number of subjects: 868

Group type: COMPARATOR
Intervention: interferon alfa‐2a plus ribavirin (HCV genotype 1)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin (HCV genotype 2 or 3)
Number of subjects: 868

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo (HCV genotype 2 or 3)
Number of subjects: 868

Group type: COMPARATOR
Intervention: interferon alfa‐2a plus ribavirin (HCV genotype 2 or 3)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: ribavirin
Number of subjects: 868
Study: 12584575

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study: 9690944

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of erythropoietin (Epoetin beta)
Number of subjects: 0
Study: 8080985

Group type: EXPERIMENTAL
Intervention: RGD peptide matrix treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard therapy plus RGD peptide matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy plus placebo
Number of subjects: 0
Study: 2753986

Group type: EXPERIMENTAL
Intervention: Hydergine (2 mg, single oral dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydergine (2 mg, 3 times daily, chronic treatment for 4-12 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydergine (2 mg, 3 times daily, chronic treatment for 4-104 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 360247

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDZ)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 447
Study: 29203842

Group type: EXPERIMENTAL
Intervention: Clomipramine 15 mg/day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Clomipramine 30 mg/day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 27325857

Group type: COMPARATOR
Intervention: Rd continuous
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Rd18
Number of subjects: 1623
Study: 23543311

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a alone (group A)
Number of subjects: 153

Group type: COMPARATOR
Intervention: PEG‐IFNα‐2a/RBV (group B)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Weekly PEG‐IFNα‐2a (group C)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Biweekly therapy (group D)
Number of subjects: 153

Group type: COMPARATOR
Intervention: PEG‐IFNα‐2a/RBV (group E)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a/RBV/fluvastatin (group F)
Number of subjects: 153
Study: 24237718

Group type: EXPERIMENTAL
Intervention: Parental training programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 20804630

Group type: EXPERIMENTAL
Intervention: Cranberry powder (1500 mg per day for 6 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no cranberry treatment)
Number of subjects: 42
Study: 18001723

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 16613274

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture-anesthesia device (EAAD) used for localizing brachiplex nerve blocking
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paresthesia elicitation used for localizing brachiplex nerve blocking (Control)
Number of subjects: 120
Study: 14983613

Group type: EXPERIMENTAL
Intervention: Lipid clinic model intervention including diet, medication, and follow-up by nurses and physicians.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice control group treatment by general internists.
Number of subjects: 0
Study: 10925523

Group type: EXPERIMENTAL
Intervention: Healthy emmetropic or ametropic eyes
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Eyes with ocular hypertension
Number of subjects: 291
Study: 8826204

Group type: EXPERIMENTAL
Intervention: Behavior training group (N=67)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (N=39)
Number of subjects: 106
Study: 1314147

Group type: EXPERIMENTAL
Intervention: Fragmin (5000 IU subcutaneously once daily for six days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 2982534

Group type: EXPERIMENTAL
Intervention: Oral administration of sodium bicarbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of ammonium chloride
Number of subjects: 0
Study: 30368584

Group type: EXPERIMENTAL
Intervention: H3B-6527 (200 mg dose) after a high-fat meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: H3B-6527 (200 mg dose) after fasting
Number of subjects: 12
Study: 29901710

Group type: EXPERIMENTAL
Intervention: Mediterranean Pattern with 500 g lean, unprocessed red meat (Med-Red)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mediterranean Pattern with 200 g lean, unprocessed red meat (Med-Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both Med-Red and Med-Control
Number of subjects: 41
Study: 27036221

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 300
Study: 23971520

Group type: EXPERIMENTAL
Intervention: STAR (Start. Transform. Achieve. Results.) intervention
Number of subjects: 1145
Study: 22179735

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 3 g daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: EASi-QoL
Number of subjects: 1000

Group type: COMPARATOR
Intervention: ASQoL
Number of subjects: 1000
Study: 20223454

Group type: EXPERIMENTAL
Intervention: 100mg of mifepristone every 30 days for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 36
Study: 18807577

Group type: EXPERIMENTAL
Intervention: D-003 5 mg/d
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15622150

Group type: EXPERIMENTAL
Intervention: Experimental group (not specified)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 21
Study: 11936486

Group type: EXPERIMENTAL
Intervention: Prokarin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 10421537

Group type: EXPERIMENTAL
Intervention: Chemoradiation (5000 cGy, Cisplatin 75 mg/m2, Fluorouracil 1000 mg/m2 for 4 days)
Number of subjects: 119
Study: 8789470

Group type: EXPERIMENTAL
Intervention: Proximal anastomoses of vein grafts sutured after aortic declamping during partial occlusion of the aorta (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proximal anastomoses done during aortic cross‐clamping (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aortic cross‐clamping (Group B)
Number of subjects: 60
Study: 3225664

Group type: EXPERIMENTAL
Intervention: Uterine activity monitoring
Number of subjects: 67

Group type: COMPARATOR
Intervention: Palpation for contractions
Number of subjects: 67
Study: 29471068

Group type: EXPERIMENTAL
Intervention: Low calorie diet (LCD)
Number of subjects: 123
Study: 28760210

Group type: EXPERIMENTAL
Intervention: 0/1-hour high-sensitivity troponin T (hs-TnT) protocol
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Usual care of standard troponin reporting evaluated at 3 and 6 hours
Number of subjects: 5400
Study: 25623276

Group type: EXPERIMENTAL
Intervention: perioperative nutrition
Number of subjects: 280

Group type: COMPARATOR
Intervention: no nutrition
Number of subjects: 280
Study: 24108526

Group type: EXPERIMENTAL
Intervention: Esmolol (continuous infusion titrated to maintain heart rate between 80/min and 94/min)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 154
Study: 21079437

Group type: EXPERIMENTAL
Intervention: Catcher's mask
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 0
Study: 18414904

Group type: EXPERIMENTAL
Intervention: Vortex port
Number of subjects: 200

Group type: COMPARATOR
Intervention: Celsite port
Number of subjects: 200
Study: 21106625

Group type: EXPERIMENTAL
Intervention: CPAP (n=169)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Sham CPAP (n=171)
Number of subjects: 340
Study: 15668416

Group type: EXPERIMENTAL
Intervention: Intraduodenal levodopa/carbidopa infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional combination therapies
Number of subjects: 24
Study: 12036647

Group type: EXPERIMENTAL
Intervention: Topical ropivacaine 1%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Topical lidocaine 4%
Number of subjects: 64
Study: 9782681

Group type: EXPERIMENTAL
Intervention: CNS prophylactic chemotherapy
Number of subjects: 47
Study: 7945600

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements in a quiet environment (high setting: 76 mm Hg, low setting: 138 mm Hg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements in a moving ambulance (high setting: 76 mm Hg, low setting: 138 mm Hg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison of quiet environment vs moving ambulance measurements
Number of subjects: 49
Study: 2905187

Group type: EXPERIMENTAL
Intervention: Fraxiparin (7500 anti-Xa units, once daily)
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Calcium heparin (5000 units, three times daily)
Number of subjects: 1896
Study: 12528545

Group type: EXPERIMENTAL
Intervention: Total flavones of Hippophae rhamnoides L. (TFH)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Calcium antagonist nifedipine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Verapamil ER
Number of subjects: 88
Study: 31680083

Group type: EXPERIMENTAL
Intervention: 1% amitriptyline gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% amitriptyline mouthwash
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard conventional treatment
Number of subjects: 30
Study: 29481765

Group type: EXPERIMENTAL
Intervention: ASSIST-linked brief intervention (10-step BI) for illicit drug use
Number of subjects: 171

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 171
Study: 27267518

Group type: EXPERIMENTAL
Intervention: NaCl 6.0%
Number of subjects: 69

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 69
Study: 25481829

Group type: EXPERIMENTAL
Intervention: Tailored Navigation Intervention (TNI)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 764
Study: 22763801

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg for weeks 1-4, 40 mg for weeks 5-8
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)
Number of subjects: 941

Group type: COMPARATOR
Intervention: Losartan potassium (LOS) 50 mg for weeks 1-4, 100 mg for weeks 5-8
Number of subjects: 941

Group type: COMPARATOR
Intervention: Losartan potassium (LOS)
Number of subjects: 941
Study: 20103392

Group type: EXPERIMENTAL
Intervention: Walking stick
Number of subjects: 46
Study: 17562406

Group type: EXPERIMENTAL
Intervention: Mid-vastus split without patellar eversion
Number of subjects: 122

Group type: COMPARATOR
Intervention: Mid-vastus split with patellar eversion
Number of subjects: 122

Group type: COMPARATOR
Intervention: Median parapatellar arthrotomy without patellar eversion
Number of subjects: 122
Study: 15611036

Group type: EXPERIMENTAL
Intervention: Glucose supplementation during prolonged exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo during prolonged exercise
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prolonged exercise (3 hours)
Number of subjects: 13
Study: 11907289

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily for a minimum of 12 weeks
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks followed by 250 mg twice daily for a minimum of 12 weeks
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Bosentan (both doses)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 10331997

Group type: EXPERIMENTAL
Intervention: Parent initiated preschool surveillance group
Number of subjects: 538

Group type: COMPARATOR
Intervention: Conventional preschool surveillance group
Number of subjects: 538
Study: 8579005

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (IT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 36
Study: 2505730

Group type: EXPERIMENTAL
Intervention: Lithium carbonate added to carbamazepine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lithium alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 15
Study: 605912

Group type: EXPERIMENTAL
Intervention: Breathing 100 ppm of carbon monoxide for 1 hour
Number of subjects: 10

Group type: COMPARATOR
Intervention: Compressed, purified air for 1 hour
Number of subjects: 10
Study: 30392864

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and motivational interviewing family-based weight loss treatment
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Continued skills training
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Relapse prevention
Number of subjects: 186
Study: 28237048

Group type: EXPERIMENTAL
Intervention: Maintaining Abstinence (MA)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cold Turkey (CT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Winding Down (WD)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Generalized Estimating Equations (GEE) analyses
Number of subjects: 128

Group type: COMPARATOR
Intervention: Early treatment PDD (weeks 1‐7)
Number of subjects: 128
Study: 25492848

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fasting conditions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fed conditions
Number of subjects: 60
Study: 24290112

Group type: EXPERIMENTAL
Intervention: Supervised light‐ to moderate‐intensity exercise intervention (3 days a week, 50‐55 minutes per session)
Number of subjects: 962

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 962
Study: 21622825

Group type: EXPERIMENTAL
Intervention: Sodium ascorbate (10 mM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 11
Study: 19500381

Group type: EXPERIMENTAL
Intervention: Intravenous iron (500 mg iron polymaltose, single dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral iron (2 ferrous sulphate slow-release tablets daily)
Number of subjects: 100
Study: 16686720

Group type: EXPERIMENTAL
Intervention: 1% ethanol in 1.5% glycine irrigation fluid
Number of subjects: 120
Study: 14611916

Group type: EXPERIMENTAL
Intervention: Postoperative thoracic radiotherapy
Number of subjects: 3000
Study: 11763947

Group type: EXPERIMENTAL
Intervention: Standard Cure (Optilux 401) for 60 s
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stepped Curing (Elipar Highlight) for 10 s low intensity followed by 50 s high intensity
Number of subjects: 120
Study: 8964851

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spironolactone (SP)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 2000902

Group type: EXPERIMENTAL
Intervention: Partial tenonectomy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Total tenonectomy
Number of subjects: 49
Study: 6391157

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily for three weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 63
Study: 30644762

Group type: EXPERIMENTAL
Intervention: Forsus plus miniplates (FMP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Miniplates
Number of subjects: 48
Study: 29409728

Group type: COMPARATOR
Intervention: Extended-release niacin (ERN) treatment
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Baseline GlycA levels
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: In-trial GlycA levels
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Low levels of small HDL particles (baseline)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Low levels of small HDL particles (in-trial)
Number of subjects: 2754
Study: 26616764

Group type: EXPERIMENTAL
Intervention: Calisthenic exercise
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cycle exercise
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 47
Study: 24588631

Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 476

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 476